Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects ≥ 18 years of age who have signed informed consent~* Philadelphia positive Chronic Myeloid Leukemia (CML) in chronic phase~* Previously untreated chronic phase CML, except for Anagrelide or Hydroxyurea.~* Eastern Co-Operative Group (ECOG) Performance Status (PS) Score 0 - 2~Exclusion Criteria:~* Known Abl-kinase T315I or T315A mutation~* Serious or uncontrolled medical disorder (including infection or cardiovascular disease) or dementia or other serious psychiatric condition~* Prior chemotherapy.~* Women who are pregnant or breastfeeding or Women of Child Bearing Potential (WOCBP) who are unwilling or unable to use an acceptable method to avoid pregnancy during the entire study period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1: Dasatinib (Type: ACTIVE_COMPARATOR): None
- Arm2: Dasatinib + BMS-833923 (Type: EXPERIMENTAL): Dasatinib for 1 year followed by dasatinib plus BMS-833923 for 2 years followed by dasatinib alone for approximately 2 years; depending on response

Based on this trial design, predict the completion outcome and termination type (if applicable).